Focus: Vir Biotechnology is a San Francisco-based biotech focused on infectious disease therapies with a diversified pipeline spanning COVID-19, influenza, hepatitis B/D, and emerging oncology programs. The company is positioned as a clinical-stage to early-commercial biotech with multiple assets advancing through Phase 2–3 development.
Profile data last refreshed 6h ago · AI intelligence enriched 3w ago
Stable — net +2 jobs in 30d
11 added, 9 removed. Backfill posture.
Best fit for career-builders seeking high-impact infectious disease exposure in a growth-stage biotech; not ideal for those prioritizing near-term revenue stability or commercial-launch experience.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Vir Biotechnology
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Vir Biotechnology's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Vir Biotechnology Appoints Brent Sabatini as Interim Principal Financial Officer - Contract Pharma
Vir Biotechnology Appoints Brent Sabatini as Interim Principal Financial Officer Contract Pharma
Why Is Vir Biotechnology (NASDAQ:VIR) Turning Heads In Small-Caps? - Kalkine Media
Why Is Vir Biotechnology (NASDAQ:VIR) Turning Heads In Small-Caps? Kalkine Media
Vir Biotechnology Announces Appointment of Timothy Coughlin to its Board of Directors - businesswire.com
Vir Biotechnology Announces Appointment of Timothy Coughlin to its Board of Directors businesswire.com
How Marianne De Backer saved Vir after flu drug failure - The Business Journals
How Marianne De Backer saved Vir after flu drug failure The Business Journals
Gilead wins hepatitis D drug approval as two Bay Area rivals line up their drugs - The Business Journals
Gilead wins hepatitis D drug approval as two Bay Area rivals line up their drugs The Business Journals
Vir Biotechnology Stock Has Nearly Doubled in a Year. One Major Holder Just Trimmed $17 Million - The Motley Fool
Vir Biotechnology Stock Has Nearly Doubled in a Year. One Major Holder Just Trimmed $17 Million The Motley Fool
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo